TABLE OF CONTENTS
1 INTRODUCTION 119
1.1 OBJECTIVES OF THE STUDY 119
1.2 MARKET DEFINITION 119
1.3 OVERVIEW OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET 119
1.4 LIMITATIONS 121
1.5 MARKETS COVERED 121
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 CURRENCY AND PRICING 129
2.5 DBMR TRIPOD DATA VALIDATION MODEL 130
2.6 MULTIVARIATE MODELLING 133
2.7 PRODUCT TYPE LIFELINE CURVE 133
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.9 DBMR MARKET POSITION GRID 135
2.10 MARKET TESTING TYPE COVERAGE GRID 136
2.11 VENDOR SHARE ANALYSIS 137
2.12 SECONDARY SOURCES 138
2.13 ASSUMPTIONS 138
3 EXECUTIVE SUMMARY 139
4 PREMIUM INSIGHTS 142
4.1 PORTERS FIVE FORCES 145
4.2 PESTEL ANALYSIS 146
5 EPIDEMIOLOGY 147
6 PIPELINE ANALYSIS FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET 148
7 REGULATORY FRAMEWORK 149
8 MARKET OVERVIEW 151
8.1 DRIVERS 153
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 153
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 153
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 155
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 155
8.2 RESTRAINS 156
8.2.1 HIGH COST OF ANTIVIRAL DRUGS 156
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 156
8.3 OPPORTUNITIES 157
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 157
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 157
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 158
8.4 CHALLENGES 159
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 159
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 160
9 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION 161
9.1 OVERVIEW 162
9.2 INFLUENZA 165
9.2.1 NEURAMINIDASE INHIBITORS 166
9.2.1.1 OSELTAMIVIR 166
9.2.1.2 ZANAMIVIR 166
9.2.1.3 PERAMIVIR 166
9.2.1.4 LANINAMIVIR 166
9.2.2 M2 INHIBITORS 167
9.2.2.1 RIMANTADINE 167
9.2.2.2 OTHERS 167
9.2.3 RNA POLYMERASE INHIBITORS 167
9.2.3.1 FAVIPIRAVIR 167
9.2.3.2 BALOXAVIR MARBOXIL 167
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 168
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 169
9.3.1.1 NUCLEOSIDE (NRTIS) 169
9.3.1.1.1 LAMIVUDINE 170
9.3.1.1.2 ABACAVIR 170
9.3.1.1.3 DIDANOSINE 170
9.3.1.1.4 OTHERS 170
9.3.1.2 NONNUCLEOSIDE (NNRTIS) 170
9.3.1.2.1 EFAVIRENZ 170
9.3.1.2.2 NEVIRAPINE 170
9.3.1.2.3 DELAVIRDINE 170
9.3.1.2.4 OTHERS 171
9.3.1.3 INTEGRASE 171
9.3.1.3.1 DOLUTEGRAVIR 171
9.3.1.3.2 ELVITEGRAVIR 171
9.3.1.3.3 RALTEGRAVIR 171
9.3.1.3.4 BICTEGRAVIR 171
9.3.1.4 NUCLEOTIDE 171
9.3.1.4.1 TENOFOVIR 172
9.3.1.4.2 OTHERS 172
9.3.1.5 INTERFERONS 172
9.3.1.5.1 ALPHA 172
9.3.1.5.2 BETA 172
9.3.1.5.3 GAMMA 173
9.3.1.6 GP41 173
9.3.1.6.1 ENFUVIRTIDE 173
9.3.1.6.2 OTHERS 173
9.3.2 PROTEASE 174
9.3.2.1 ATAZANAVIR 174
9.3.2.2 DARUNAVIR 174
9.3.2.3 LOPINAVIR 174
9.3.2.4 RITONAVIR 174
9.3.2.5 SAQUINAVIR 174
9.3.2.6 INDINAVIR 174
9.3.2.7 NELFINAVIR 175
9.3.2.8 TIPRANAVIR 175
9.3.2.9 AMPRENAVIR 175
9.4 HEPATITIS C VIRUS 175
9.4.1 NS5B POLYMERASE 176
9.4.1.1 SOFOSBUVIR 176
9.4.1.2 DASABUVIR 176
9.4.2 NS3/4A PROTEASE 177
9.4.2.1 DANOPREVIR 177
9.4.2.2 GLECAPREVIR 177
9.4.2.3 GRAZOPREVIR 177
9.4.2.4 PARITAPREVIR 177
9.4.2.5 SIMEPREVIR 177
9.4.3 NS5A PHOSPHOPROTEIN 178
9.4.3.1 LEDIPASVIR 178
9.4.3.2 VELPATASVIR 178
9.4.3.3 OMBITASVIR 178
9.4.3.4 ELBASVIR 178
9.4.3.5 DACLATASVIR 178
9.4.3.6 PIBRENTASVIR 178
9.4.4 NEURAMINIDASE 179
9.4.4.1 OSELTAMIVIR 179
9.4.4.2 ZANAMIVIR 179
9.4.4.3 PERAMIVIR 179
9.4.4.4 LANINAMIVIR 179
9.4.5 RNA POLYMERASE 179
9.4.5.1 BALOXAVIR MARBOXIL 180
9.4.5.2 FAVIPIRAVIR 180
9.4.6 MATRIX PROTEIN 2 180
9.4.6.1 RIMATIDINE 180
9.4.6.2 FAVIPIRAVIR 180
9.5 HERPES SIMPLEX VIRUS 181
9.5.1 DNA POLYMERASE UL30 182
9.5.1.1 ACICLOVIR 182
9.5.1.2 FAMCICLOVIR 182
9.5.1.3 VALACICLOVIR 182
9.5.1.4 PENCICLOVIR TRIFLURIDINE 182
9.5.1.5 BRIVUDINE 182
9.5.1.6 FOSCARNET 182
9.5.1.7 IDOXURIDINE 183
9.5.2 ENVELOPE PROTEINS 183
9.5.2.1 DOCOSANOL 183
9.5.2.2 OTHERS 183
9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 183
9.6.1 GANCICLOVIR 184
9.6.2 VALGANCICLOVIR 184
9.6.3 CIDOFOVIR 184
9.6.4 FOSCARNET 184
9.6.5 FOMIVIRSEN 184
9.7 VARICELLA-ZOSTER VIRUS (VZV) 185
9.7.1 VALACICLOVIR 186
9.7.2 FAMCICLOVIR 186
9.7.3 ACICLOVIR 186
9.7.4 VIDARABINE 186
9.7.5 BRIVUDINE 186
9.8 HEPATITIS B VIRUS 186
9.8.1 ENTECAVIR 187
9.8.2 TENOFOVIR 187
9.8.3 TELBIVUDINE 187
9.8.4 TENOFOVIR ALAFENAMIDE 188
9.8.5 OTHERS 188
9.9 RESPIRATORY SYNCYTIAL VIRUS 188
9.9.1 RNA POLYMERASE 189
9.9.1.1 RIBAVIRIN 189
9.9.1.2 OTHERS 189
9.9.2 FUSION GLYCOPROTEIN 189
9.9.2.1 PALIVIZUMAB 190
9.9.2.2 OTHERS 190
9.10 CORONAVIRUS INFECTION 190
9.11 OTHERS 191
10 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 192
10.1 OVERVIEW 193
10.2 GERIATRIC 196
10.2.1 MALE 196
10.2.2 FEMALE 196
10.3 CHILD 197
10.3.1 MALE 197
10.3.2 FEMALE 198
10.4 ADULT 198
10.4.1 MALE 199
10.4.2 FEMALE 199
11 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS 200
11.1 OVERVIEW 201
11.2 ORAL 204
11.2.1 SOLID 205
11.2.1.1 TABLETS 205
11.2.1.2 CAPSULES 205
11.2.1.3 OTHERS 205
11.2.2 SEMISOLID 205
11.2.2.1 GELS 206
11.2.2.2 EMULSIONS 206
11.2.2.3 ELIXIRS 206
11.2.2.4 OTHERS 206
11.2.3 LIQUID 206
11.2.3.1 SOLUTIONS 206
11.2.3.2 SYRUPS 206
11.2.3.3 OTHERS 206
11.3 TOPICAL 207
11.3.1 SEMI-SOLID 208
11.3.1.1 CREAM 208
11.3.1.2 OINTMENT 208
11.3.1.3 GELS 208
11.3.1.4 OTHERS 208
11.3.2 LIQUID 208
11.3.2.1 SOLUTIONS 209
11.3.2.2 SUSPENSIONS 209
11.3.3 SOLID 209
11.3.3.1 POWDERS 209
11.3.3.2 SUPPOSITORIES 209
11.3.3.3 ENEMA 209
11.3.3.4 OTHERS 209
11.4 PARENTERAL 210
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 211
11.4.1.1 SOLUTIONS 211
11.4.1.2 RECONSTITUTED/LYOPHILIZED 211
11.4.1.3 SUSPENSIONS 211
11.4.1.4 EMULSIONS 211
11.4.1.5 OTHERS 211
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 212
11.4.3 COLLOIDAL DISPERSIONS 212
11.4.4 LONG ACTING INJECTION FORMULATION 212
12 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 213
12.1 OVERVIEW 214
12.2 GENERIC 217
12.3 BRANDED 217
13 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER 218
13.1 OVERVIEW 219
13.2 HOSPITAL 222
13.3 SPECIALTY CENTERS 222
13.4 AMBULATORY CENTRES 223
13.5 CLINICS 223
13.6 HOME HEALTHCARE 223
13.7 OTHERS 224
14 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 225
14.1 OVERVIEW 226
14.2 HOSPITAL PHARMACY 229
14.3 RETAIL PHARMACY 229
14.4 ONLINE PHARMACY 230
15 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY REGION 231
15.1 ASIA-PACIFIC 232
15.1.1 JAPAN 254
15.1.2 CHINA 270
15.1.3 SOUTH KOREA 286
15.1.4 INDIA 304
15.1.5 AUSTRALIA 321
15.1.6 SINGAPORE 339
15.1.7 THAILAND 357
15.1.8 MALAYSIA 374
15.1.9 INDONESIA 391
15.1.10 PHILIPPINES 409
15.1.11 VIETNAM 427
15.1.12 REST OF ASIA-PACIFIC 444
16 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 445
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 445
17 SWOT ANALYSIS 446

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.